Sector
PharmaceuticalsOpen
₹255.1Prev. Close
₹264.1Turnover(Lac.)
₹31.25Day's High
₹299Day's Low
₹255.152 Week's High
₹30052 Week's Low
₹156.4Book Value
₹68.94Face Value
₹10Mkt Cap (₹ Cr.)
176.26P/E
95.86EPS
2.95Divi. Yield
015 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
25 May 2024
12:00 AM
AGM
Announcement Date: 25 May, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 35.73 | 27.97 | 25.29 | 22.35 |
Net Worth | 41.96 | 34.2 | 31.52 | 28.58 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 50.86 | 54.25 | 43.79 | 40.79 |
yoy growth (%) | -6.24 | 23.88 | 7.34 | 14.99 |
Raw materials | -32.78 | -28.54 | -24.48 | -24.71 |
As % of sales | 64.44 | 52.62 | 55.9 | 60.59 |
Employee costs | -6.23 | -6.03 | -5.27 | -3.69 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3.87 | 10.5 | 5.64 | 4.72 |
Depreciation | -1.01 | -1.03 | -1.02 | -0.93 |
Tax paid | -1.02 | -3.32 | -1.58 | -1.19 |
Working capital | 9.94 | 7.87 | 2.34 | 1.93 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.24 | 23.88 | 7.34 | 14.99 |
Op profit growth | -58.85 | 82.52 | -1.18 | 44.09 |
EBIT growth | -57.12 | 79.49 | 5.02 | 45.54 |
Net profit growth | -60.37 | 77.07 | 14.87 | 332.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672.5 | 93.86 | 4,01,288.77 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,833.1 | 82.12 | 1,81,397.34 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,485.05 | 24.92 | 1,19,948.65 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,313.15 | 59.26 | 1,12,127.01 | 474 | 0.18 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,578 | 56.47 | 1,06,401.47 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sharat Deorah
Whole-time Director
Siddhartha Deorah
Independent Director
Kavita Vijayakant Sharma
Whole-time Director
Kiran Kulkarni
Independent Director
Vishal Kailash Chandra Jhunjhunwala
Independent Director
Mahendra Kumar Daga
Company Sec. & Compli. Officer
Priyanka Gupta
K-56 MIDC Indl Area,
Tarapur Boisar,
Maharashtra - 401506
Tel: 91-22-66635456
Website: http://www.aurolabs.com
Email: auro@aurolabs.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 91-22-23016761/8261
Website: -
Email: -
Summary
Auro Laboratories Ltd, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API). Currently, the Company is specializing in producing Anti Diabetics like Me...
Read More
Reports by Auro Laboratories Ltd
What is the Auro Laboratories Ltd share price today?
What is the Market Cap of Auro Laboratories Ltd?
What is the PE and PB ratio of Auro Laboratories Ltd?
What is the 52 Week High and Low of Auro Laboratories Ltd?
What is the CAGR of Auro Laboratories Ltd?
What is the shareholding pattern of Auro Laboratories Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.